American Society of Hematology

How I Treat Leukemia

The following "How I Treat" sessions on leukemia took place at the 2018 ASH Meeting on Hematologic Malignancies. View the full schedule and program.

How I Treat Newly Diagnosed and Relapsed ALL

This talk with focus on the use of novel therapies, including antibodies (blinatumomab, inotuzumab), in the treatment of both newly diagnosed and relapsed/refractory acute lymphocytic leukemia. In addition, Dr. Anjali Advani will review ongoing clinical trials, evaluating kinase inhibitors in the treatment of newly diagnosed Philadelphia chromosome-like acute lymphocytic leukemia.

Anjali Advani, MD, Cleveland Clinic

Anjali Advani

Anjali Advani, MD, is director of the Inpatient Leukemia Program and a staff physician in the Department of Hematology/Oncology at the Cleveland Clinic. She is an associate professor at the Cleveland Clinic Lerner College of Medicine and chair of the Data Safety and Monitoring Board for Case Comprehensive Cancer Center. Dr. Advani’s research focuses on novel therapies for acute lymphocytic and acute myeloid leukemia. She is a member of the SWOG Leukemia Committee, where she is the national principal investigator for several clinical trials in acute leukemia.

back to top

How I Treat Mutations and MRD in the Care of AML Patients

Jessica Altman, MD, Northwestern University

back to top

How I Test Patients With CLL at Diagnosis and Relapse and How I Use the Results

Paul Barr, MD, University of Rochester

back to top

How I Treat AML in the Elderly

Jeffrey Lancet, MD, Moffitt Cancer Center

back to top

How I Treat Using the Newly FDA-Approved Drugs in AML

Gail Roboz, MD, Weill Cornell Medical College

Gail J_ Roboz

Gail J. Roboz, MD, is a professor of medicine and director of the Clinical and Translational Leukemia Program at the Weill Medical College of Cornell University and the New York Presbyterian Hospital. She has an active clinical practice for patients with acute and chronic leukemias, myelodysplastic syndrome, bone marrow failure states, and myeloproliferative neoplasms.

Dr. Roboz’s research interests are in developmental therapeutics and novel clinical trials for these areas. She has served as the principal investigator on many investigator-initiated, cooperative group, and industry-sponsored clinical trials and has authored or coauthored numerous manuscripts and abstracts. Dr. Roboz sits on the editorial boards of and acts as a reviewer for several journals. She has played an active role as an invited speaker and panelist at numerous regional, national, and international conferences. Dr. Roboz also serves on the Medical Advisory Board of the Aplastic Anemia and MDS International Foundation.

back to top